Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Pozzi

Showing results (31-40 of 32) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 32 results.
Breast (Edinburgh, Scotland)|February 18, 2004
c-erbB 2 serum level as prognostic factor in hormonally treated advanced breast cancer patientsN Zilembo, L Mariani, A Martinetti, et al.
Leukemia|July 20, 2007
The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cellsJ Golay, L Cuppini, F Leoni, et al.
Pageof 4

Showing results (31-40 of 32) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 32 results.
Breast (Edinburgh, Scotland)|February 18, 2004
c-erbB 2 serum level as prognostic factor in hormonally treated advanced breast cancer patientsN Zilembo, L Mariani, A Martinetti, et al.
Leukemia|July 20, 2007
The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cellsJ Golay, L Cuppini, F Leoni, et al.
Pageof 4